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Abstract 
The inflammatory milieu favors recruitment and activation of osteoclasts, and leads to bone 
destruction as a serious complication associated with arthritis and with other inflammatory processes. 
The frequency and activity of osteoclast progenitors (OCPs) correspond to arthritis severity, and may 
be used to monitor disease progression and bone resorption, indicating the need for detailed 
characterization of the discrete OCP subpopulations. Collectively, current studies suggest that the most 
potent murine bone marrow OCP population can be identified among lymphoid negative population 
within the immature myeloid lineage cells, as B220–CD3–CD11b–/loCD115+CD117+CX3CR1+ and 
possibly also Ter119–CD11c–CD135loLy6C+RANK–. In the peripheral blood OCP population bears the 
monocytoid phenotype B220–CD3–NK1.1–CD11b+Ly-6ChiCD115+CX3CR1+, presumably expressing 
RANK in committed OCPs. Much less is known about human OCPs and their regulation in arthritis, 
but the circulating OCP subset is, most probably, comprised among the lymphoid negative population 
(CD3–CD19–CD56–), within immature monocyte subset (CD11b+CD14+CD16–), expressing receptors 
for M-CSF and RANKL (CD115+RANK+). Our preliminary data confirmed positive association 
between the proportion of peripheral blood OCPs, defined as CD3–CD19–CD56–CD11b+CD14+, and 
the disease activity score (DAS28) in the follow-up samples from patient with psoriatic arthritis 
receiving anti-TNF therapy. In addition, we reviewed cytokines and chemokines which, directly or 
indirectly, activate OCPs and enhance their differentiation potential, thus mediating osteoresorption. 
Control of the activity and migratory behavior of OCPs as well as the identification of crucial 
bone/joint chemotactic mediators represent promising therapeutic targets in arthritis.  
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1. Inflammation induced bone loss 
Bone is a highly dynamic tissue important for its mechanical and metabolic functions, and 
characterized by rapid response to numerous physical, endocrine and paracrine stimuli in 
physiological and pathological conditions. Among others signals, osteoresorptive mediators (such as 
interleukin (IL)-1, IL-6, IL-15, IL-17, IL, 21, IL-33, tumor necrosis factor (TNF)-α and receptor 
activator of nuclear factor-κB ligand (RANKL), CCL2, CXCL12) produced by inflammatory/immune 
cells create conditions that promote maturation and function of osteoclasts [1-4]. Bone resorption and 
osteolysis are the prominent features and causes of substantial morbidity in inflammatory processes 
associated with arthritis as well as with localized bacterial infections of bone and adjacent tissues, 
peri-prosthetic loosening, vasculitis, connective tissue diseases, chronic viral infections and 
inflammatory bowel diseases [5-8]. 
 
2. Bone resorption in arthritis 
Inflammatory arthritides comprise a heterogeneous group of joint disorders that are characterized by 
chronic inflammatory response as well as periarticular and generalized bone loss due to deregulated 
bone remodeling [1, 4, 9, 10]. Disruption of joint architecture and bone erosions are the hallmarks of 
rheumatoid arthritis (RA) but also occur in spondyloarthritis (SpA) and the erosive form of 
osteoarthritis (OA) [1, 5, 8, 9, 11-13].  
Inflamed synovial tissue in RA, with increased vascularity, hyperplasia and accumulation of 
macrophages, plasma cells, T and B lymphocytes, dendritic cells (DC), natural killer (NK) cells and 
mast cells, was traditionally postulated as the major pathogenic factor invading adjacent structures 
(articular cartilage, cortical bone surface and underlying bone marrow) [11, 12]. However, more recent 
evidence revealed that inflammatory processes in RA spread well beyond the synovial tissue 
inflammation, particularly affecting subchondral compartment [1, 9].  
Most prominent subchondral changes include cortical bone erosions and diffuse bone marrow edema 
[1, 8, 9, 14]. The bone marrow pathology in the form of bone marrow edema is present at all stages of 
RA, associated with the disease activity, and also described in OA, SpA and systemic lupus 
erythematosus. Pathophysiological correlate of bone marrow edema is osteitis, with inflammatory 
infiltrate (comprised of T and B lymphocytes, plasma cells and macrophages) and active osteoclasts 
closely juxtaposed to trabecular bone mediating the erosive processes [9, 14].  
Moreover, the presence of generalized bone loss, manifested as lower bone mineral density and higher 
rate of pathological fractures, has been observed in different forms of arthritides and associated with 
the disease severity. Although generalized osteoporosis in arthritis was usually attributed to 
immobility and corticosteroid treatment, more recent studies suggest that systemic osteopenia as well 
as periarticular bone loss and local erosions are caused at least in part by a common pathogenic 
mechanism that involves inflammation-induced increase in osteoclast number and activity [14-17]) 
However, the frequency of osteoclast progenitor (OCP) populations, serving as a pool for osteoclast 
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renewal and maintenance of the expanded osteoclast number, and their migration patterns through 
peripheral blood and bone sites have not been precisely defined in inflammatory arthritides.  
 
3. Differentiation of osteoclasts 
As the exclusive osteoresorptive cells, osteoclasts are directly responsible for physiological bone 
resorption and pathological bone destruction [18,19]. They arise from myeloid hematopoietic 
progenitor cells of the monocyte/macrophage lineage through a series of differentiation stages that 
generate large multinucleated, tartrate-resistant acid phosphatase (TRAP)-positive mature cells [20, 
21]. Abnormally enhanced osteoclast formation and activity accelerate pathogenesis of arthritis and 
other diseases characterized by inflammatory osteolysis, causing bone loss that inevitably results in 
pain, deformity, osteopenia and structural changes [2, 3, 5, 18, 19].  
Osteoclast differentiation is physiologically triggered by RANKL/RANK binding, in the presence of 
macrophage colony stimulating factor (M-CSF/CSF-1) [22-24], and these essential osteoclastogenic 
molecules are abundantly expressed in inflammatory conditions such as arthritis and periodontitis [3, 
8]. RANKL, expressed on osteoblasts and hypertrophying chondrocytes, as well as on activated T 
lymphocytes, is up-regulated by pro-resorptive hormones, cytokines and inflammatory mediators, 
including vitamin D3, parathyroid hormone, prostaglandin E2 (PGE2), IL-1, IL-6, IL-7, IL-17 and IL-
22 [5, 7, 8]. RANKL pathway is inhibited by osteoprotegerin (OPG), a soluble decoy receptor for 
RANKL, and RANKL/OPG ratio is a key determinant of the rate of osteoclastogenesis and bone 
resorption [5, 20]. The increased RANKL/OPG ratio in synovial compartment results in enhanced 
osteoclast differentiation and formation of bone erosions [2, 3, 7, 8] 
M-CSF, through its receptor cFms (CSF-1R/CD115), and the transcription factor PU.1 are involved in 
the generation of common progenitors for macrophages, DCs and osteoclasts. M-CSF induces the 
proliferation of OCPs, supports their survival and upregulates RANK expression [23, 24]. IL-34, by 
binding to cFms, is able to replace M-CSF in RANKL-induced osteoclastogenesis [7, 8, 25]. 
RANK lacks the intrinsic enzymatic activity in its intracellular domain and transduces signaling by 
recruiting adaptor molecules from the TRAF (TNF receptor-associated factor) family of proteins, 
mainly TRAF6 [23, 24]. Upon RANK/TRAF6 complex formation, multiple signaling pathways are 
activated, including classical and alternative NF-κB pathways, protein tyrosine kinases (BtK/Tec), 
calcium signaling and mitogen-activated protein kinase (MAPK) pathways (p38 and Erk). These 
signaling cascades potently induce transcription factor NFATc1 (nuclear factor of activated T cells, 
cytoplasmic 1), which is a key regulator of osteoclast differentiation in vitro and in vivo. It positively 
regulates its own promoter and cooperates with other partners to activate the osteoclast transcriptional 
machinery [5, 8]. Particularly, activator protein 1 (AP-1) transcription factor complex containing cFos 
is required for autoamplification of NFATc1 and osteoclast differentiation. AP-1 DNA binding 
activity has been found to be upregulated in the synovial tissue of RA patients and correlates with the 
disease activity [5, 23]. The costimulatory receptors OSCAR (osteoclast associated receptor) and 
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TREM2 (triggering receptor expressed by myeloid cells 2) enhance the osteoclastogenic signal 
through immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor proteins (DNAX-
activating protein of 12 kDa (DAP12) and Fc-receptor γ chain (FcRγ)) and Syk tyrosine kinase 
activation [5, 7, 8, 23, 24]. 
 
4. Characterization of osteoclast progenitors 
Given their central role in the osteolytic processes, osteoclast lineage cells (including OCPs) have 
become a focus of studies investigating inflammatory osteoresorption [1, 4, 5, 8, 9, 13, 18, 19]. 
Osteoclasts create bone erosions by resorbing periarticular and subchondral bone over a period of 
months to years, although an individual osteoclast life span is much shorter (2 to 4 weeks) [10, 18, 19, 
26]. Thus, mature osteoclasts must be constantly renewed by OCPs in order to sustain pathological 
bone resorption [8, 9, 24]. Characterization of the discrete OCP subpopulations has become necessary 
to elucidate the effects of systemic and local stimuli, such as hormones and cytokines/chemokines, on 
the recruitment and homing of OCPs, on their differentiation to mature osteoclasts, as well as on their 
activity and lifespan [2, 4, 19, 21]. In this review we have focused on studies defining surface marker 
expression profile of OCPs, which were further functionally tested in osteoclastogenic in vitro assays 
and osteoresorptive in vivo arthritic models/diseases.  
 
4.1. Murine osteoclast progenitors 
Physiologically, OCPs reside within the bone marrow, spleen and peripheral-blood mononuclear cell 
(PBMC) pools (Table 1). Investigations of murine bone marrow have identified immature myeloid 
CD117+CD115+RANK– cells as progenitors with the ability to differentiate into osteoclasts and DCs in 
vitro [27]. In addition, a rare (0.1-0.3%) highly osteoclastogenic population was characterized among 
lymphoid negative population within immature myeloid subset, expressing a phenotype B220–CD3–
CD11b–/loCD115+ and the variable level of CD117 (cKit), with CD117hi cells being the most potent in 
generating osteoclasts [28]. Further dissection revealed B220–CD3–CD11b–
/loCD115+CD117+CX3CR1+ cells as a common bone marrow progenitors for osteoclasts, macrophages 
and DCs at the single-cell clonal level, expressing, to a certain degree, other myeloid markers such as 
Ly6C and F4/80 [29, 30]. By using different combination of surface markers, Xiao et al identified a 
common bone marrow progenitor for osteoclasts, DCs and macrophages, characterized as B220–
CD117+CD115+CD11bloCD27hi. In a mouse model of chronic immune activation, sustained 
CD27/CD70 interaction caused an arrest in osteoclast differentiation and accumulation of OCPs 
suggesting a skewing toward DC differentiation [31].  
Additional two studies attempted to define the OCP subpopulations in murine models of arthritis. 
Human TNF-α transgenic (hTNF-Tg) mice had a significant increase in bone marrow proliferating 
CD11b+Gr-1(Ly6G)–/lo cells as well as circulating CD11b+Gr-1(Ly6G)–/lo cells [32]. Bone marrow and 
peripheral blood CD11b+Gr-1(Ly6G)–/lo cells efficiently differentiated into TRAP+ osteoclasts upon 
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stimulation with M-CSF and RANKL. In addition, TNF-α treatment in vitro stimulated proliferation 
and the conversion of CD11b+Gr-1–/loC115– to CD11b+Gr-1–/loCD115+ osteoclastogenic cells. In the 
Sakaguchi (SKG) mouse model of inflammatory arthritis myeloid OCPs, identified as a CD3–B220–
Ter119–CD11b–/loLy6Chi population, expanded in bone marrow and had the capacity to differentiate 
into multinucleated bone-resorbing osteoclasts in vitro and in vivo [33]. These OCPs were further 
characterized as being CD135loCD11c–CX3CR1+CD115+RANK– and not uniform in the expression of 
CD117 and osteoclastogenic potential of single-cell clones. Described OCP population was distinct 
from bone marrow monocyte DC progenitors, but retained the plasticity to differentiate into DCs and 
macrophages under appropriate culture conditions. In addition, OCPs shared the phenotype with the 
myeloid-derived suppressor cell (MDSC) population and exerted an immunomodulatory function upon 
a co-adoptive transfer with SKG CD4+ T lymphocytes. Sawant et al also observed that bone marrow 
CD11b+Gr-1+CD80loCD115+F4/80– MDSCs of breast tumor-bearing mice, found among the immature 
myeloid population, can be differentiated into functional osteoclasts [34]. 
Cells with osteoclastogenic potential also exist in blood and peripheral hematopoietic organs. Both 
splenic and peripheral blood monocyte progenitors have been identified to share the B220–CD3–
NK1.1–CD11b+Ly-6ChiCD115+CX3CR1+ phenotype, with the capacity to differentiate into 
osteoclasts, macrophages and DCs. This OCP population was negative for the granulocyte marker 
Ly6G and expressed intermediate level of CD117 [30]. Circulating long-lived quiescent lineage-
committed OCPs (QOPs) were characterized as CD115loRANKhi cells, with almost no expression of 
myeloid markers CD11b, F4/80 and Gr-1, and were also present in very low numbers in bone marrow 
[35]. In response to different osteoclastogenic stimuli QOPs had the potential to differentiate into 
osteoclasts in vitro and in vivo [35, 36]. 
In models of arthritis in vivo, great expansion of CD11b+RANK+ splenocytes was observed, possibly 
serving as a source of osteoclasts responsible for bone destruction in collagen induced arthritis (CIA) 
established in the IFN-γR knock-out mice [37]. Another study using the CIA model revealed that in 
vivo depletion of CD11b+Gr-1+CCR2+ monocytes by anti-CCR2 antibody significantly attenuated the 
severity of arthritis [38]. Systemic increase in TNF-α has been shown to mediate an enlargement of 
peripheral CD11bhiCD115+ OCP population in the hTNF-Tg mouse model. Expanded CD11bhi 
splenocyte population was negative for CD3, B220, F4/80 and CD117, and inhomogeneous for Gr-1 
and RANK (<20% cells) [39]. 
Chemokine receptor expression, attributed to OCPs, is crucial for their selective attraction to bone and 
subsequent sustained pathological bone resorption in arthritis [5, 8, 40, 41]. Besides the already 
described expression of CX3CR1 (fractalkine (CX3CL1) receptor) and CCR2 (receptor for monocyte 
chemotactic protein 1 (MCP-1)/CCL2) [29, 33, 42], OCPs also express CXCR4, a receptor for stromal 
cell-derived factor 1 (SDF-1/CXCL12), secreted by bone marrow stromal cells, vascular endothelium 
and immature osteoblasts [40, 41, 43]. 
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4.2. Human osteoclast progenitors 
Peripheral blood monocyte pool, originating from myeloid bone marrow progenitors, contains DC and 
macrophage progenitors as well as, at low frequency, OCPs (Table 2). It was estimated that 1-2% of 
peripheral blood monocytes are capable of differentiating into osteoclasts under physiological 
conditions [44-46]. Circulatory OCPs, found in higher frequency in arthritic patients, migrate to bone 
surfaces attracted by osteoclastogenic signals and subsequently differentiate into osteoclasts creating 
bone erosions [46, 47].  
Several monocyte markers were used, such as CD11b, CD14, CD16 or CD51/61, to purify human 
peripheral OCPs and test their osteoclastogenic potential in vitro, upon treatment with cytokines 
(including RANKL, M-CSF, TNF-α, IL-6, IL-17 and IL-32), synovial fibroblasts or synovial fluid 
from arthritic patients [47-57]. The osteoclast forming capacity of CD14+ cells has been observed to 
be higher compared with CD11b+ or CD61+ cells [53], and to correspond to the expression level of 
CD16 and DC-STAMP (dendritic cell-specific transmembrane protein) [54]. Under in vitro 
osteoclastogenic conditions CD14+ monocytes acquired CD51/61 (integrin αvß3/vitronectin receptor) 
and CD16 (FcRγIII) markers. Among the circulatory CD14+CD11b+CD51/61+ monocyte population, 
CD14hiCD16+ subset was significantly increased in multiple myeloma patients [55]. Peripheral blood 
and bone marrow CD14+RANKhi monocytes differentiated more efficiently into osteoclasts compared 
with CD14+RANKint and CD14+RANKlo cells. Moreover, CD45+CD14+CD51/61+CD115+RANK+ 
cells were identified as committed OCPs in a giant cell tumor of bone [56]. Although OCPs express β2 
integrins such as CD11b/CD18, CD11b expression seems to be a negative regulator of the earliest 
stages of osteoclast differentiation by transiently suppressing RANK expression. The RANKL signal 
induced a switch in the integrin expression from β2 to β3 on CD14+ OCPs, attenuating the β2 integrin 
negative role in osteoclastogenesis [47]. 
Monocytes can be dissected based on the expression of CD16, into CD16+ and CD16– subsets that 
differ in their migratory pattern, cytokine profile and lineage commitment [44, 46, 57]. In 
physiological conditions, OCPs have been found among CD14+CD16– monocyte pool, possibly within 
the subset of immature (proliferating) monocytes (defined as CD14+CD16–
CD64+CD33+CD13loCD115+) [58]. Komano et al described a highly osteoclastogenic subpopulation of 
peripheral blood monocytes, expressing the CD14+CD16–(CD33hi)CD115lo phenotype [46]. However, 
the CD16+ subset increases in inflammatory conditions and migrates into the sites of inflammation 
[44, 46]. Peripheral blood samples from patients with PsA, particularly those with bone erosions, 
showed significantly expanded OCP population that resides within the CD14+CD16+ monocyte pool 
[57]. A marked expansion of CD16+ monocytes in peripheral blood and their accumulation in the 
synovial tissue was also reported in RA. This monocyte subset overlapped with human cartilage gp-39 
expression (a possible autoantigen in RA), did not express lymphoid markers (CD3–CD4–CD8–CD20–
CD56–), but weakly expressed some other myeloid markers (CD33loMHCIIloCD14lo) [59]. However, 
CD16– cells also accumulate in RA synovium, and differ from CD16+ cells by their expression of 
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CD51/61, which is important for committed OCP migration and associated with osteoclast maturation 
[46, 47]. Described results indicate that CD14+CD16+ monocytes represent a more mature (mostly 
quiescent) stage in osteoclast differentiation sequence compared with CD14+CD16– and CD14+CD16int 
subsets [57, 58]  
Although the cell-surface phenotype of peripheral OCPs has been extensively studied in arthritis, the 
functional relations of circulating OCPs to bone marrow OCPs and their bone-directed homing, mostly 
governed by chemokine signals, have not been clearly established. CXCR4, unique CXCL12 receptor, 
is highly expressed in human OCPs and mature osteoclasts, indicating that CXCL12 may be important 
for chemotaxis, differentiation and survival of human osteoclast lineage cells [60]. CCR1 and CCR5, 
which interact with inflammatory protein 1α (MIP-1α/CCL3), have been detected in bone marrow 
derived OCPs, able to generate osteoclasts in vitro when stimulated with MIP-1α [61]. 
Osteoclastogenic potential of peripheral blood was identified as biomarker of erosive disease in RA, 
psoriatic arthritis (PsA) and other forms of SpA [5, 46, 52, 53, 56, 57, 59]. Based on our previous 
study, which showed the osteoclastogenic potential of CD3–CD19–CD56–CD14+CD11b+ PBMCs [52], 
we assessed the association in the frequency of such OCPs and clinical disease activity score (DAS28) 
in the follow-up samples of PsA patients during anti-TNF treatment (Enbrel, 50 mg/week) (Figure 1). 
Our results revealed positive correlation between the proportion of peripheral OCP and DAS28 score 
(in 3 out of 4 patients) as well as reduction of both parameters with anti-TNF treatment (in 2 out of 4 
patients), suggesting favorable therapeutic response (Figure 1).  
 
4.3. Effect of arthritic mediators on osteoclast progenitors 
Under pathological arthritic conditions, the process of osteoclastogenesis is markedly enhanced by 
various innate and acquired immune mediators, particularly proinflammatory cytokines, which act on 
OCPs directly or indirectly, through RANK/RANKL/OPG system [3, 17, 20]. It has been shown that 
even a small rise in the level of systemic inflammation can precipitate osteodestruction [2, 21, 62]. 
Thus, investigation of factors that promote osteoclast activity may provide insight into the events 
responsible for the pathological bone loss seen in arthritis. Due to the length constrain, we are 
discussing only the positive regulators of OCPs and their described roles in arthritis (Figure 2). 
Additional positive and negative regulators of osteoclast differentiation and activity associated with 
inflammatory conditions have been identified and extensively reviewed by several recent publications 
[5-8]. 
The altered cytokine profile created by inflammatory cells is a crucial part of arthritis ethyology, with 
proinflammatory cytokines (elevated systemically and produced within synovial compartment) 
playing a key role in arthritic bone destruction [5-8, 40, 41, 63]. Particularly, TNF- α potently induces 
osteoclastogenesis through several mechanisms: by upregulating RANK expression in OCPs and 
RANKL expression in osteoblasts and synovial fibroblasts; by affecting OCPs directly and 
independently of RANKL; and by inducing M-CSF expression in bone marrow stromal cells [32, 39, 
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64, 65]. TNF-induced bone loss is highly dependent on IL-1, and IL-1-deficient hTNF-Tg mice show 
no bone loss and cartilage destruction. IL-1 stimulates osteoclastogenesis by increasing production of 
RANKL, M-CSF and PGE2 in osteoblast lineage cells, while decreasing OPG [64, 66]. IL-6, induced 
by TNF-α, contributes to bone destruction by stimulating RANKL expression and by regulating 
development of Th17 lymphocytes [67]. TNF-α upregulates IL-34, which mediates chemotactic 
migration of OCPs and supports the RANKL-induced osteoclastogenesis in the absence of M-CSF 
[25]. 
Besides the activation of proinflammatory loop by innate immune cells, Th17 lymphocytes and 
associated cytokine profile have also been proven to mediate development of inflammatory arthritis [5, 
7]. IL-17, a hallmark Th17 cytokine, stimulates bone destruction and is present in the synovium of RA 
patients. It is also produced by mast cells, a major source of IL-17 in inflammatory arthritis. In vitro, 
IL-17 stimulates osteoclastogenesis mostly indirectly by inducing RANKL expression (in osteoblasts 
and synovial fibroblasts) and production of proinflammatory cytokines (IL-6, IL-8, TNF-α and IL-1), 
but may also upregulate RANK in human OCPs and act in a RANKL-independent manner [68]. Some 
potent arthritic mediators exert their effects in synergy with IL-17, such as IL-23, which is able to 
elicit severe arthritis with a profound bone-resorptive phenotype. It enhances osteoclast differentiation 
by upregulating RANK expression in peripheral blood OCPs [69]. IL-32, induced by IL-17, stimulates 
TNF-α and IL-1β production, and promotes maturation of OCPs independently of RANKL [70] 
Other cytokines contribute to the pathology of arthritis mainly by increasing RANKL expression in 
CD4+ T lymphocytes or synovial fibroblasts. IL-7 induces overexpression of RANKL in T 
lymphocytes and its blockade significantly reduces monocyte attraction, osteoclast differentiation and 
bone erosion in CIA [71]. IL-21 stimulates osteoclastogenesis through an induction of RANKL in 
CD4+ T lymphocytes, and is upregulated in the synovia and sera of RA patients [72]. Although its role 
in osteoclastogenesis is still controversial, IL-18 is known to induce M-CSF, GM-CSF, RANKL and 
OPG in synovial fibroblasts and/or T lymphocytes [73]. IL-22 promotes osteoclastogenesis in RA by 
upregulating RANKL expression in synovial fibroblasts, through the p38 MAPK/NF-κB and JAK-
2/STAT-3 pathways [74]. In contrast, SOFAT (secreted osteoclastogenic factor of activated T-cells), 
produced by activated T lymphocytes, induces osteoclastogenesis independently of RANKL. As 
chronic T lymphocyte activation is involved in RA etiology, SOFAT can present additional link in the 
cross-talk between bone and immune cells in arthritis [75]. 
Several cytokines overexpressed in synovial tissue may act directly on OCPs, mediating arthritic 
processes. Besides the already described TNF-α and IL-32, IL-33 induces osteoclastogenesis from 
human monocytes, by activating MAPKs, NF-κB and Syk/PLCγ pathways independently of RANKL 
[76]. IL-15 directly promotes differentiation of rodent OCPs to preosteoclasts in vitro, through the 
MAPKs and NF-κB pathways, but also upregulates RANKL expression in synovial fibroblasts [77]. 
Although some of the proinflammatory cytokines (ie IL-6, IL-18, IL-33) may exhibit the anti-
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osteoclastogenic effects, it mostly applies to the early stages of osteoclastogenesis, whereas in chronic 
inflammatory conditions these cytokines predominately work as pro-osteoclastogenic mediators [5, 6] 
Chemoattractants directing the homing of OCPs from circulation to bone sites are not fully 
characterized [7, 8, 40, 41]. Among the best defined is CXCL12, which directly promotes early stages 
of osteoclast development. It also attracts OCPs to bone surfaces, and activates T lymphocytes and 
synovial fibroblasts in RA to secrete RANKL [43, 60, 78]. CCL20 is over-expressed in subchondral 
bone in RA, and is able to induce OCP expansion and osteoclast differentiation [79] Although 
treatment of RA patients with anti-CCL2 antibody failed to produce clinical improvement, recent 
studies revealed that serum CCL2 level is associated with osteoclastogenic potential of peripheral 
blood OCPs and clinical markers of arthritis activity [52, 80]. 
 
5. Conclusions 
In vivo plasticity, as a hallmark of the myeloid lineage, enables the flexible lineage commitment of 
monocyte progenitors toward osteoclasts, macrophages or DCs, depending on the cytokine and 
chemokine milieu in the bone marrow, circulation and synovium. Within the pool of immature 
monocytes, OCPs are found in higher frequency in the peripheral blood and synovial tissue of patients 
with RA and SpA, mediating bone loss locally, in the form of bone erosions and joint osteolysis, and 
systemically, with loss of skeletal bone density. Moreover, the size and activity of OCP population 
corresponds to arthritis severity, and may be used to monitor disease progression and bone resorption. 
Thus, osteoclasts represent a functional link between joint inflammation and structural damage in 
arthritis. However, the human OCP subpopulations are not yet precisely defined and it is, still, unclear 
by which exact mechanisms the cytokine/chemokine network induces activation and egress of OCPs 
from hematopoietic organs and attracts them to joint and bone lesions. A number of 
immunomodulatory treatments aimed to inhibit osteoclast differentiation and activity are in use or 
under investigation, including biological therapies aimed to block IL-1, TNF-α, IL-6 and RANKL, but 
with only partial effect in reducing bone resorption. Control of the migratory behavior of OCPs and 
identification of crucial bone/joint chemotactic mediators represent promising therapeutic targets in 
arthritis, with the fine dissection of the discrete OCP populations being the necessary prerequisite for 
such approaches.  
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Table 1. Surface marker expression profile of mouse osteoclast progenitor populations  
 
Osteoclast progenitor phenotype Source
a
 Reference 
CD117+CD115+RANK– BM 27 
B220–CD3–CD11b–/loCD115+CD117+CX3CR1+ 
B220–CD3–NK1.1–CD11b+Ly-6ChiCD115+CX3CR1+ 
BM 
PBL, SPL 
28, 29, 30 
B220–CD117+CD115+CD11bloCD27hi BM 31 
CD115loRANKhi (mostly CD11b–F4/80–Gr-1–) BM, PBL 35 
CD11b+Gr-1+CD80loCD115+F4/80– BM (TM) 34 
CD11b+Gr-1+CCR2+ PBL, SYN (CIA) 38 
CD3–B220–Ter119–CD11b–/loLy6Chi 
CD135loCD11c–CD115+CD117+CX3CR1+RANK– 
BM (SKG) 33 
CD11b+Gr-1(Ly6G)–/lo BM, PBL (hTNF-Tg) 32 
B220–CD3–F4/80–CD117–CD11bhiCD115+ SPL (hTNF-Tg) 39 
CD11b+RANK+ SPL (IFN-γR KO CIA) 37 
 
a Osteoclast progenitors, capable of differentiating into functional osteoclasts, were characterized 
using multiple surface markers by flow-cytometry, in bone marrow (BM), peripheral blood (PBL), 
spleen (SPL) and synovium (SYN), in wild type and genetically modified mice under physiological 
and pathological conditions. RANK, receptor activator of nuclear factor-κB; TM, breast-tumor bearing 
mice; SKG, Sakaguchi model of arthritis; hTNF-Tg, human tumor necrosis factor α transgenic model 
of arthritis; IFN-γR KO, interferon γ receptor knock-out mice; CIA, collagen induced arthritis. 
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Table 2 Surface marker expression profile of human osteoclast progenitor populations  
 
Osteoclast progenitor phenotype Source
a
 Reference 
CD14+; CD11b+; or CD61+ PBL 53 
CD3–CD19–CD56–CD14+CD11b+ PBL 52 
CD14+CD11b+ (intß1+intß2+intß3–) PBL 47 
CD14hiCD11b+CD51/61+CD16+ PBL (MM) 55 
CD14+RANKhi 
CD45+CD14+CD51/61+CD115+RANK+ 
PBL, BM 
GCT 
56 
CD14+CD16–(CD33hi)CD115lo PBL, SYN (RA) 46 
CD16+(gp-39): CD3–CD4–CD8–CD20–CD56–CD33loMHCIIloCD14lo PBL, SYN (RA) 59 
CD14+CD16+DC-STAMP+ PBL (PsA) 54 
CD14+(MHCII+)CD16+ PBL (PsA) 57 
 
a Osteoclast progenitors, capable of differentiating into functional osteoclasts, were characterized 
using multiple surface markers by flow-cytometry in bone marrow (BM), peripheral blood (PBL) and 
synovium (SYN), in control samples and patients with malignant (multiple myeloma (MM), giant cell 
tumor of bone (GCT)) and chronic joint diseases (psoriatic arthritis (PsA), rheumatoid arthritis RA). 
RANK, receptor activator of nuclear factor-κB; int, integrin; DC-STAMP, dendritic cell-specific 
transmembrane protein; gp-39, human cartilage gp-39,a possible autoantigen in RA; MHC, major 
histocompatibility complex. 
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Figure legends 
 
Figure 1. Effect of anti-TNF-α therapy on osteoclast progenitors in psoriatic arthritis. Peripheral 
blood samples of patients with psoriatic arthritis (PsA; 2 females/2 males, age range 47-67 years, 
arthritis duration range 8-14 years, with the clinical form of spondylitis with peripheral arthritis; with 
the approval of the Ethics Committee and informed consent) were collected in a time-course of anti-
TNF-α therapy (Enbrel, 50 mg/week): immediately prior to therapy introduction (ctrl), and at month 1 
(1m), month 3 (3m) and month 6 (6m) of the treatment. Peripheral-blood mononuclear cells were 
analyzed for the frequency of osteoclast progenitors (OCPs), bearing phenotype CD3–CD19–CD56–
CD14+CD11b+, by flow-cytometry. A) Sorted OCPs were differentiated by the addition of RANKL 
(60 ng/mL) and M-CSF (40 ng/mL), and analyzed for the presence of TRAP+ osteoclast-like cells at 
day 12 of culture; representative image. B) Dynamic changes in OCP frequency during the follow-up 
period of TNF-α therapy. Density plots represent the percentages of lymphoid negative cells (CD3–
CD19–CD56–) in the context of monocytoid CD14 and CD11b markers for the representative patient. 
C) Association of OCP frequency and clinical disease activity score (DAS28) in a time-course of anti-
TNF-α therapy (patients #1 to #4). 
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Figure 2. Perpetuation of osteoclast progenitor activity by pro-resorptive cytokines and chemokines in 
arthritis. The possible scenario of exaggerated and sustained osteoresorption is initiated by 
overstimulation of osteoclast progenitor (OCP) activity by inflammatory/immune mediators. These 
mediators (mostly cytokines and chemokines), overexpressed in arthritis, can potently promote 
osteoclastogenesis by having direct (on OCPs) or indirect (through other cells in the 
microenvironment, such as stromal cells, osteoblasts, T lymphocytes and fibriblast-like synoviocytes) 
effects on RANK/RANKL expression. OCPs, generated in hematopoietic tissues in response to the 
essential osteoclastogenic factors RANKL and M-CSF, migrate either directly to the sites of bone 
resorption or are first released into circulation as quiescent osteoclast progenitors (QOPs) and then 
home to bone attracted by chemotactic mediators. Once attached to the bone surface, committed 
OCPs, highly expressing RANK, differentiate into mature bone-resorbing osteoclasts in response to 
osteoclastogenic stimuli. For clarity, only the most important positive regulators of osteoclast 
differentiation in arthritis are shown. IL, interleukin; TNF-α, tumor necrosis factor α; RANK, receptor 
activator of nuclear factor-κB; RANKL, RANK ligand; M-CSF, macrophage colony-stimulating 
factor; cFms, M-CSF receptor; CXCR/CCR, chemokine receptors.  
 
 
 
